Centene (CNC) Q4 2024 Earnings Transcript

Centene reported Q4 adjusted diluted EPS of $0.80 and full-year EPS of $7.17, both ahead of prior guidance, while raising 2025 premium and service revenue guidance by $4 billion to $158 billion-$160 billion. Management reaffirmed 2025 adjusted EPS above $7.25 and plans for $2 billion of buybacks, supported by stronger Medicare AEP results, Medicare Stars improvement, and mid-4% Medicaid rate increases. Cash flow was weak at $154 million for 2024, but management expects normalization in 2025 as working-capital timing reverses.

Analysis

Centene is de-risking the near-term P&L while preserving upside optionality, which is a better setup than the headline guidance change implies. The real lever is not the added revenue itself, but the mix shift: higher Medicaid rates, stronger Medicare retention, and a larger PDP book should improve the quality of earnings into 2H25 and 2026, even if 1H cash conversion remains noisy.

The market is likely underestimating how much of the Medicaid reset is now behind the company. If rate filings keep catching up to acuity through the year, 2025 margin progression should look less like a one-off rebound and more like a multi-year normalization trade. That matters because buybacks become much more valuable when the company is both reducing share count and exiting a period of artificially depressed Medicaid profitability.

The bigger contrarian issue is that the stock may be too cheap for the wrong reasons. Consensus likely still treats marketplace and PDP as cyclical or policy-fragile, but management is effectively signaling these are structurally higher-quality earnings streams than the market models. The risk is timing: if ACA membership attrition or FTR-related losses hit harder in Q2, investors could get a temporary sentiment air pocket even if the full-year economics remain intact.

For competitors, the more important second-order effect is pressure on smaller managed care players that lack Centene’s scale in ACA and PDP. If Centene is willing to use pricing power and technology/automation to defend share while pulling capital back through repurchases, peers with weaker administrative leverage may face margin compression before they can reprice. In other words, this is less about one quarter and more about Centene extending its cost and distribution advantage into a better capital-return machine.

Key Decisions for Investors

• Long CNC on a 3-6 month horizon ahead of Q2 membership clarity; base case is multiple expansion as investors gain confidence that Medicaid rate normalization and PDP scale translate into durable EPS, with downside cushioned by the >$2B buyback authorization.
• Sell downside protection or fund the long with a put spread: buy CNC common and sell 6-9 month out-of-the-money puts to monetize elevated policy/membership uncertainty; attractive if you believe the Q2 surprise risk is more timing than economics.
• Pair trade: long CNC / short ELV or HUM over the next 2 quarters to express relative strength in ACA/PDP execution and buyback support versus peers more exposed to slower earnings inflection and less visible capital return.
• If headline risk around ACA membership creates a selloff in the next 4-8 weeks, add aggressively rather than chase strength; the best entry likely comes before April FTR reconciliation data resolves, not after.
• Avoid outright shorting healthcare managed care here; the asymmetric risk is to the upside if Medicaid rates keep improving and the market starts capitalizing Centene's earnings power at a higher multiple.